Strategies to incorporate left atrial appendage occlusion into clinical practice

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The left atrial appendage (LAA) has been identified as a predominant source of thrombus formation leading to significant thromboembolic events in patients with nonvalvular atrial fibrillation. Medical therapy to eliminate thrombus formation in the LAA has been the standard of care for several decades, but mechanical approaches designed to exclude the LAA from the circulation have recently been developed. The largest body of randomized and nonrandomized data to date has been for the Watchman device (Boston Scientific, Natick, Massachusetts), which was recently approved by the Food and Drug Administration for selected patients in the United States. There are no current guidelines or guidance for institutions and operators looking to become involved in this therapy. This perspective is aimed at exploring these issues and providing necessary information and guidance to these programs and operators to help ensure a successful launch of a LAA occlusion program and optimize patient selection, procedural performance, and outcome.

Original languageEnglish (US)
Pages (from-to)2337-2344
Number of pages8
JournalJournal of the American College of Cardiology
Volume65
Issue number21
DOIs
StatePublished - Jun 2 2015

Fingerprint

Atrial Appendage
Thrombosis
United States Food and Drug Administration
Standard of Care
Atrial Fibrillation
Patient Selection
Guidelines
Equipment and Supplies
Therapeutics

Keywords

  • anticoagulant agent(s)
  • atrial fibrillation
  • stroke prevention
  • thromboembolism

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Strategies to incorporate left atrial appendage occlusion into clinical practice. / Alli, Oluseun; Asirvatham, Samuel J; Holmes, David.

In: Journal of the American College of Cardiology, Vol. 65, No. 21, 02.06.2015, p. 2337-2344.

Research output: Contribution to journalArticle

@article{c04d984fdfc84b69a8506dff3ebfaacc,
title = "Strategies to incorporate left atrial appendage occlusion into clinical practice",
abstract = "The left atrial appendage (LAA) has been identified as a predominant source of thrombus formation leading to significant thromboembolic events in patients with nonvalvular atrial fibrillation. Medical therapy to eliminate thrombus formation in the LAA has been the standard of care for several decades, but mechanical approaches designed to exclude the LAA from the circulation have recently been developed. The largest body of randomized and nonrandomized data to date has been for the Watchman device (Boston Scientific, Natick, Massachusetts), which was recently approved by the Food and Drug Administration for selected patients in the United States. There are no current guidelines or guidance for institutions and operators looking to become involved in this therapy. This perspective is aimed at exploring these issues and providing necessary information and guidance to these programs and operators to help ensure a successful launch of a LAA occlusion program and optimize patient selection, procedural performance, and outcome.",
keywords = "anticoagulant agent(s), atrial fibrillation, stroke prevention, thromboembolism",
author = "Oluseun Alli and Asirvatham, {Samuel J} and David Holmes",
year = "2015",
month = "6",
day = "2",
doi = "10.1016/j.jacc.2015.03.564",
language = "English (US)",
volume = "65",
pages = "2337--2344",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "21",

}

TY - JOUR

T1 - Strategies to incorporate left atrial appendage occlusion into clinical practice

AU - Alli, Oluseun

AU - Asirvatham, Samuel J

AU - Holmes, David

PY - 2015/6/2

Y1 - 2015/6/2

N2 - The left atrial appendage (LAA) has been identified as a predominant source of thrombus formation leading to significant thromboembolic events in patients with nonvalvular atrial fibrillation. Medical therapy to eliminate thrombus formation in the LAA has been the standard of care for several decades, but mechanical approaches designed to exclude the LAA from the circulation have recently been developed. The largest body of randomized and nonrandomized data to date has been for the Watchman device (Boston Scientific, Natick, Massachusetts), which was recently approved by the Food and Drug Administration for selected patients in the United States. There are no current guidelines or guidance for institutions and operators looking to become involved in this therapy. This perspective is aimed at exploring these issues and providing necessary information and guidance to these programs and operators to help ensure a successful launch of a LAA occlusion program and optimize patient selection, procedural performance, and outcome.

AB - The left atrial appendage (LAA) has been identified as a predominant source of thrombus formation leading to significant thromboembolic events in patients with nonvalvular atrial fibrillation. Medical therapy to eliminate thrombus formation in the LAA has been the standard of care for several decades, but mechanical approaches designed to exclude the LAA from the circulation have recently been developed. The largest body of randomized and nonrandomized data to date has been for the Watchman device (Boston Scientific, Natick, Massachusetts), which was recently approved by the Food and Drug Administration for selected patients in the United States. There are no current guidelines or guidance for institutions and operators looking to become involved in this therapy. This perspective is aimed at exploring these issues and providing necessary information and guidance to these programs and operators to help ensure a successful launch of a LAA occlusion program and optimize patient selection, procedural performance, and outcome.

KW - anticoagulant agent(s)

KW - atrial fibrillation

KW - stroke prevention

KW - thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=84930038993&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930038993&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2015.03.564

DO - 10.1016/j.jacc.2015.03.564

M3 - Article

C2 - 26022824

AN - SCOPUS:84930038993

VL - 65

SP - 2337

EP - 2344

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 21

ER -